ArticleFrontiers in endocrinology2025
Multimodal MRI radiomics-clinical fusion model predicts intravenous glucocorticoid response in thyroid eye disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop a multimodal MRI radiomics-clinical fusion model for predicting intravenous glucocorticoid (IVGC) treatment response in patients with thyroid eye disease (TED). Methods: In this retrospective multicenter study, 108 TED patients (78 responders, 30 non-responders) from two institutions (January 2020-December 2024) were included, and treatment response was assessed at 12 weeks after completion of therapy. Patients were randomly split into training and test sets (8:2). All patients received a standardized intravenous methylprednisolone regimen (total dose 4.5 g over 12 weeks) according to EUGOGO recommendations. Univariate logistic regression was used to identify clinical predictors associated with response. Radiomics features and deep transfer learning (DTL) features were extracted from pretreatment T1-weighted imaging (T1WI) and fat-suppressed T2-weighted imaging (T2WI-FS). Feature selection followed a three-step pipeline (t-test, Pearson correlation filtering, and LASSO with 10-fold cross-validation), and a radiomics-deep learning fused (RDL) model was built. A combined model integrating the RDL score with independent clinical predictors was constructed and visualized as a nomogram. Model performance was evaluated using ROC/AUC, calibration curves, and decision curve analysis (DCA), and AUCs were compared using the DeLong test. Results: Disease duration and Clinical Activity Score (CAS) were independent predictors of IVGC response (P < 0.05). The RDL model outperformed radiomics-only models, achieving AUCs of 0.894 (95% CI: 0.804-0.984) in the training set and 0.804 (95% CI: 0.595-1.000) in the test set. The combined model demonstrated further improved performance, with training and test set AUCs of 0.916 (0.837-0.994) and 0.862 (0.702-1.000), respectively, along with better calibration and higher net clinical benefit. The DeLong test showed that the AUC of the combined model was significantly higher than that of the clinical model (P = 0.032), but did not differ significantly from that of the RDL model (P = 0.161). Conclusion: The multimodal MRI radiomics-clinical fusion model accurately predicts IVGC treatment response in TED, offering a non-invasive tool for personalized therapy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.